RT Journal Article
SR Electronic
T1 Controlled human malaria infection with PvW1 – a new clone of <em>Plasmodium vivax</em> with high quality genome assembly
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.23.21259839
DO 10.1101/2021.07.23.21259839
A1 Minassian, Angela M.
A1 Themistocleous, Yrene
A1 Silk, Sarah E.
A1 Barrett, Jordan R.
A1 Kemp, Alison
A1 Quinkert, Doris
A1 Nielsen, Carolyn M.
A1 Edwards, Nick J.
A1 Rawlinson, Thomas A.
A1 Lopez, Fernando Ramos
A1 Roobsoong, Wanlapa
A1 Ellis, Katherine J.
A1 Cho, Jee-Sun
A1 Aunin, Eerik
A1 Otto, Thomas D.
A1 Reid, Adam J.
A1 Bach, Florian
A1 Labbé, Geneviève M.
A1 Poulton, Ian D.
A1 Marini, Arianna
A1 Zaric, Marija
A1 Mulatier, Margaux
A1 Ramon, Raquel Lopez
A1 Baker, Megan
A1 Mitton, Celia H.
A1 Sousa, Jason C.
A1 Rachaphaew, Nattawan
A1 Kumpitak, Chalermpon
A1 Maneechai, Nongnuj
A1 Suansomjit, Chayanut
A1 Piteekan, Tianrat
A1 Hou, Mimi M.
A1 Khozoee, Baktash
A1 Roberts, David J.
A1 Lawrie, Alison M.
A1 Blagborough, Andrew M.
A1 Nugent, Fay L.
A1 Taylor, Iona J.
A1 Johnson, Kimberly J.
A1 Spence, Philip J.
A1 Sattabongkot, Jetsumon
A1 Biswas, Sumi
A1 Rayner, Julian C.
A1 Draper, Simon J.
YR 2021
UL http://medrxiv.org/content/early/2021/07/24/2021.07.23.21259839.abstract
AB Controlled human malaria infection (CHMI) provides a highly informative means to investigate host-pathogen interactions and enable in vivo proof-of-concept efficacy testing of new drugs and vaccines. However, unlike Plasmodium falciparum, well-characterized P. vivax parasites that are safe and suitable for use in modern CHMI models are limited. Here, two healthy malaria-naïve UK adults with universal donor blood group were safely infected with a clone of P. vivax from Thailand by mosquito-bite CHMI. Parasitemia developed in both volunteers and, prior to treatment, each volunteer donated blood to produce a cryopreserved stabilate of infected red blood cells. Following stringent safety screening, the parasite stabilate from one of these donors (“PvW1”) was thawed and used to inoculate six healthy malaria-naïve UK adults by blood-stage CHMI, at three different dilutions. Parasitemia developed in all volunteers, who were then successfully drug treated. PvW1 parasite DNA was isolated and sequenced to produce a high quality genome assembly by using a hybrid assembly method. We analysed leading vaccine candidate antigens and multigene families, including the Vivax interspersed repeat (VIR) genes of which we identified 1145 in the PvW1 genome. Our genomic analysis will guide future assessment of candidate vaccines and drugs, as well as experimental medicine studies.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03377296 and NCT03797989Funding StatementThis work was funded in part by the European Union Horizon 2020 research and innovation programme under grant agreement 733073 for MultiViVax; the UK Medical Research Council (MRC) Confidence in Concept Scheme at the University of Oxford [MC_PC_16056]; and by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). No third party funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK NHS Research Ethics Service (Oxfordshire Research Ethics Committee A, Ref 17/SC/0389); and UK NHS Research Ethics Service (South Central Hampshire A Research Ethics Committee), Ref 18/SC/0577.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests for materials should be addressed to the corresponding authors. PvW1 genomic assembly and annotation data can be found at: ftp://ngs.sanger.ac.uk/scratch/project/pathogens/ea10/pvivax/renamed_scaffolds/ ftp://ngs.sanger.ac.uk/scratch/project/pathogens/ea10/pvivax/renamed_scaffolds/